Skip to content
10-Q

Quarterly Report

MADRIGAL PHARMACEUTICALS, INC. MDGL

0001628280-26-030947

← back to feed
Filed
May 6, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 1, 2026 23.06M sh
Shares Diluted Q1 2026 · Mar 31, 2026 29.03M sh
Shares Diluted Q1 2026 · Dec 31, 2025 28.41M sh
Shares Diluted Q1 2026 · Sep 30, 2025 28.51M sh
Shares Diluted Q1 2026 · Sep 30, 2025 28.28M sh
Shares Diluted Q1 2026 · Jun 30, 2025 28.23M sh
Shares Diluted Q1 2026 · Jun 30, 2025 28.16M sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 28.09M sh
Shares Diluted Q1 2026 · Dec 31, 2024 26.91M sh
Shares Diluted Q1 2026 · Dec 31, 2023 21.56M sh
Capex Q1 2026 · Mar 31, 2026 $3.85M
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$167.44M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$88.89M
Long Term Debt Q1 2026 · Mar 31, 2026 $340.33M
Long Term Debt Q1 2026 · Dec 31, 2025 $339.88M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $227.03M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $198.69M
Stockholders Equity Q1 2026 · Mar 31, 2026 $543.45M
Stockholders Equity Q1 2026 · Dec 31, 2025 $602.69M
Stockholders Equity Q1 2026 · Mar 31, 2025 $710.64M
Stockholders Equity Q1 2026 · Dec 31, 2024 $754.38M
Current Liabilities Q1 2026 · Mar 31, 2026 $338.26M
Current Liabilities Q1 2026 · Dec 31, 2025 $310.29M
Total Liabilities Q1 2026 · Mar 31, 2026 $683.87M
Total Liabilities Q1 2026 · Dec 31, 2025 $656.9M
Current Assets Q1 2026 · Mar 31, 2026 $1.18B
Current Assets Q1 2026 · Dec 31, 2025 $1.25B
Total Assets Q1 2026 · Mar 31, 2026 $1.23B
Total Assets Q1 2026 · Dec 31, 2025 $1.26B
Eps Diluted Q1 2026 · Mar 31, 2026 −$3.25
Eps Diluted Q1 2026 · Dec 31, 2025 −$10.15
Eps Diluted Q1 2026 · Sep 30, 2025 −$4.01
Eps Diluted Q1 2026 · Sep 30, 2025 −$8.12
Eps Diluted Q1 2026 · Jun 30, 2025 −$1.50
Eps Diluted Q1 2026 · Jun 30, 2025 −$4.10
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$2.61
Eps Diluted Q1 2026 · Dec 31, 2024 −$17.31
Eps Diluted Q1 2026 · Dec 31, 2023 −$17.33
Eps Basic Q1 2026 · Mar 31, 2026 −$3.25
Eps Basic Q1 2026 · Dec 31, 2025 −$10.15
Eps Basic Q1 2026 · Sep 30, 2025 −$4.01
Eps Basic Q1 2026 · Sep 30, 2025 −$8.12
Eps Basic Q1 2026 · Jun 30, 2025 −$1.50
Eps Basic Q1 2026 · Jun 30, 2025 −$4.10
Eps Basic restated Q1 2026 · Mar 31, 2025 −$2.61
Eps Basic Q1 2026 · Dec 31, 2024 −$17.31
Eps Basic Q1 2026 · Dec 31, 2023 −$17.33
Sga Expense Q1 2026 · Mar 31, 2026 $268.52M
Sga Expense Q1 2026 · Mar 31, 2025 $167.88M
Net Income Q1 2026 · Mar 31, 2026 −$94.39M
Net Income Q1 2026 · Mar 31, 2025 −$73.24M
Operating Income Q1 2026 · Mar 31, 2026 −$92.72M
Operating Income Q1 2026 · Mar 31, 2025 −$79.31M
Revenue Q1 2026 · Mar 31, 2026 $311.34M
Revenue Q1 2026 · Mar 31, 2025 $137.25M